The Glucagon Like Peptide 1 Agonist (GLP-1) market is a subset of the larger diabetes drugs market. GLP-1 agonists are a class of drugs used to treat type 2 diabetes, and are designed to mimic the effects of the hormone glucagon-like peptide-1 (GLP-1). GLP-1 agonists work by stimulating the release of insulin, reducing the amount of glucose in the blood, and slowing the rate of gastric emptying. GLP-1 agonists are typically administered via injection, and are used in combination with other diabetes medications. The GLP-1 agonist market is highly competitive, with a number of major pharmaceutical companies offering products. These include Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and Boehringer Ingelheim. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
